Effects of tropospheric O3 on trembling aspen and interaction with CO2: results from an O3-gradient and a face experiment

Over the years, a series of trembling aspen (Populus tremuloides Michx.) clones differing in O sub(3) sensitivity have been identified from OTC studies. Three clones (216 and 271[(O sub(3) tolerant] and 259 [O sub(3) sensitive]) have been characterized for O sub(3) sensitivity by growth and biomass responses, foliar symptoms, gas exchange, chlorophyll content, epicuticular wax characteristics, and antioxidant production. In this study we compared the responses of these same clones exposed to O sub(3) under field conditions along a natural O sub(3) gradient and in a Free-Air CO sub(2) and O sub(3) Enrichment (FACE) facility. In addition, we examined how elevated CO sub(2) affected O sub(3) symptom development. Visible O sub(3) symptoms were consistently seen (5 out of 6 years) at two of the three sites along the O sub(3) gradient and where daily one-hour maximum concentrations were in the range of 96 to 125 ppb. Clonal differences in O sub(3) sensitivity were consistent with our OTC rankings. Elevated CO sub(2) (200 ppm over ambient and applied during daylight hours during the growing season) reduced visible foliar symptoms for all three clones from 31 to 96% as determined by symptom development in elevated O sub(3) versus elevated O sub(3) + CO sub(2) treatments. Degradation of the epicuticular wax surface of all three clones was found at the two elevated O sub(3) gradient sites. This degradation was quantified by a coefficient of occlusion which was a measure of stomatal occlusion by epicuticular waxes. Statistically significant increases in stomatal occlusion compared to controls were found for all three clones and for all treatments including elevated CO sub(2), elevated O sub(3), and elevated CO sub(2) + O sub(3). Our results provide additional evidence that current ambient O sub(3) levels in the Great Lakes region are causing adverse effects on trembling aspen. Whether or not elevated CO sub(2) in the future will alleviate some of these adverse effects, as occurred with visible symptoms but not with epicuticular wax degradation, is unknown.